Encellin pouches $9.9m to target diabetes with cell encapsulation tech
Author: Danny Sullivan | Published on: December 13, 2023 | Last updated: December 13, 2023

Khosla and Y Combinator back UCSF spinout developing implantable pouches that release therapeutic cells when needed.
Biotech startup Encellin has landed a $9.9 million…Read More

More than just a trip – the longevity potential of psychedelics

Terran Biosciences founder on longevity-psychedelic crossovers, targeting neurodegeneration and making history.
Terran Biosciences, a CNS-focused biotech platform company, is developing transformative therapeutics and technologies for patients with neurological and psychiatric d…Read More

‘We’re turning aging research into a therapeutic category’
Rejuvenate Bio CEO on why sourcing gene therapy targets from aging research may hold the key to treating many chronic diseases.
It’s been an interesting year for Harvard spin-out Rejuvenate Bio, which is targeting age-related chronic diseases with gene therapy and cellular reprogr…Read More

UNP lands $32m to advance macrocycle therapeutics for ‘any given target’

Merck and ARTIS Ventures lead round for biotech aiming to ‘bridge the gap between small molecules and biologics.’
Biotech firm Unnatural Products (UNP) has secured $32 million in Series A funding to support the development of its platform that integrates artific…Read More

Swedish biotech lands $4m for non-drug approach to obesity and diabetes

Sigrid Therapeutics deploys micron-sized silica particles to prevent digestive enzymes from breaking down carbohydrates and fats.
Funding continues to flow for companies targeting obesity, with Swedish biotech Sigrid Therapeutics revealing it has raised $4 million in an…Read More

Fauna Bio inks $494m obesity collaboration with Lilly

Partnership aims to identify new obesity drug targets using AI discovery platform powered by data from disease-resistant mammals.
Longevity biotech Fauna Bio has signed a multi-year collaboration agreement with pharma giant Lilly worth up to $494 million for preclinical drug discovery in…Read More

Longeveron raises funds following more positive Alzheimer’s trial data

Company announces registered direct offering after revealing new data from Phase 2a trial of Lomecel-B in mild Alzheimer’s disease.
Shortly after releasing additional positive data from its Phase 2a Alzheimer’s trial, longevity biotech Longeveron (NASDAQ: LGVN) has annou…Read More

Longevity 2023: From A to…

An initial look at some of this year’s longevity news – literally. Including acid, the Amish, Amazon and Aging Hallmarks.
The longevity sector is booming with new companies exiting stealth, new products hitting the market and new research pushing the limits of both lifespan and healthspan, and we’ve published over 55…Read More

Interviews of 2023: the longevity companies

Six of our favourite interviews with companies operating at the cutting edge of longevity science.
From cellular reprogramming and SIRT6 to young blood and telomere boosting therapies, there are many different approaches being pursued by longevity companies. And we’ve spoken to them all. Here are s…Read More

Longevity 2023: …to X, Y, Z

Our second look at some of 2023’s longevity news, but this time from the other end of the alphabet, including XPRIZE, young blood and Zero.
Earlier in the week, we took a spin through a selection of longevity stories that had the letter A in common; as the year draws to a close, it’s time to flip to the other end o…Read More